Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 5:39 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 252 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Phenylephrine Clear all
Recruiting Phase 4 Interventional

Vasoactive Drugs in Intensive Care Unit

NCT02118467
View directory record Official record
Conditions
Shock
Interventions
Norepinephrine, Epinephrine, Phenylephrine, Vasopressin
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
836 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 18, 2026, 5:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of AKB-6548 on Cardiac Repolarization Intervals in Healthy Volunteers

NCT02062203
View directory record Official record
Conditions
Healthy Volunteers
Interventions
AKB-6548 (therapeutic dose), AKB-6548 (supratherapeutic dose), Placebo, Moxifloxacin
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Oct 18, 2026, 5:39 AM EDT
Completed Phase 1 Interventional

A Relative Bioavailability Study Measuring the Extent and Rate of Absorption of Different Tablet Formulations of AZD1656 in Type 2 Diabetes Mellitus (T2DM) Patients

NCT01221519
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, High Blood Sugar
Interventions
AZD1656
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 19, 2012 · Synced Oct 18, 2026, 5:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability Study in Healthy Subjects

NCT00924911
View directory record Official record
Conditions
Infections, Bacterial
Interventions
GSK1322322
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 26, 2017 · Synced Oct 18, 2026, 5:39 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Study Developed to Evaluate the Effect of ANG-3777 on QT/QTc Interval

NCT04898907
View directory record Official record
Conditions
Healthy Volunteer
Interventions
ANG-3777 (Therapeutic Dose), ANG-3777 (Supra-therapeutic Dose), Placebo, Moxifloxacin Hydrochloride
Drug
Lead sponsor
Angion Biomedica Corp
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 1, 2021 · Synced Oct 18, 2026, 5:39 AM EDT
Completed Phase 1 Interventional

A Study Comparing Oxymetazoline 1% Cream to RHOFADE

NCT05148689
View directory record Official record
Conditions
Bioequivalence
Interventions
Oxymetazoline hydrochloride Cream, 1%, Rhofade™ (oxymetazoline) cream, 1%, Placebo
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 8, 2021 · Synced Oct 18, 2026, 5:39 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of Phenylephrine 2.5%-Tropicamide 1% Microdose Ophthalmic Solution for Pupil Dilation

NCT03751631
View directory record Official record
Conditions
Mydriasis
Interventions
Tropicamide 1%-Phenylephrine 2.5% ophthalmic solution (TR/PE), Tropicamide 1% ophthalmic solution (TR), Phenylephrine 2.5% ophthalmic solution (PE)
Drug
Lead sponsor
Eyenovia Inc.
Industry
Eligibility
Not listed
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Mar 18, 2022 · Synced Oct 18, 2026, 5:39 AM EDT
Completed Phase 2 Interventional Results available

Hemodynamics and Extravascular Lung Water in Acute Lung Injury

NCT00624650
View directory record Official record
Conditions
Acute Lung Injury
Interventions
Diuresis (furosemide) part I, Fluid Bolus (crystalloid or albumin), Vasopressors (Norepinephrine, Vasopressin, Phenylephrine, Epinephrine), Dobutamine, Concentrate all drips and nutrition, Diuresis (furosemide) part II, Dialysis
Drug · Other · Procedure
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
3
States / cities
Clackamas, Oregon • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Oct 18, 2026, 5:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK2336805 Alone and With the Co-administration of TMC435 in Healthy Japanese Participants.

NCT02018536
View directory record Official record
Conditions
Healthy
Interventions
GSK2336805 30 mg, GSK2336805 60 mg, GSK2336805 120 mg, TMC435 150 mg (Treatment A), GSK2336805 60 mg (Treatment B and part of Treatment C and D), TMC435 100 mg (part of Treatment C), TMC435 150 mg (part of treatment D)
Drug
Lead sponsor
Janssen R&D Ireland
Industry
Eligibility
20 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jun 17, 2014 · Synced Oct 18, 2026, 5:39 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess Safety and Efficacy in Participants Age 40 to 55 With Presbyopia (Old Eye) Who Receive AGN-190584 in Both Eyes Twice Daily

NCT04983589
View directory record Official record
Conditions
Presbyopia
Interventions
Pilocarpine HCl, Vehicle
Drug
Lead sponsor
Allergan
Industry
Eligibility
40 Years to 55 Years
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
23
States / cities
Bakersfield, California • Glendale, California • Inglewood, California + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Oct 18, 2026, 5:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Investigate the Effects of Single Intravenous Doses of Difelikefalin (CR845) on the QTc Interval in Healthy Subjects

NCT04019574
View directory record Official record
Conditions
Healthy
Interventions
CR845 0.5 mcg/kg IV, CR845 3 mcg/kg IV, Moxifloxacin 400 mg Oral Tablet, Placebo
Drug · Other
Lead sponsor
Cara Therapeutics, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 21, 2020 · Synced Oct 18, 2026, 5:39 AM EDT
Terminated Not applicable Interventional Results available

Mechanism and Treatment of Sympathetically Maintained Pain

NCT01813149
View directory record Official record
Conditions
Complex Regional Pain Syndrome (CRPS)
Interventions
phenylephrine and clonidine, punch biopsy
Drug · Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 13, 2021 · Synced Oct 18, 2026, 5:39 AM EDT
Terminated Not applicable Interventional

Fluid Resuscitation Optimization in Surgical Trauma Patients (FROST)

NCT02742974
View directory record Official record
Conditions
Critical Illness, Trauma
Interventions
Device: FloTrac™ and EV1000™, Volume Challenge, Vasopressor Therapy, Inotropic Therapy
Device · Other · Drug
Lead sponsor
CAMC Health System
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Charleston, West Virginia
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 18, 2026, 5:39 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of Nasal Hair on Nasal Obstruction

NCT01850511
View directory record Official record
Conditions
Nasal Obstruction
Interventions
Vibrissae trimming, Application of oxymetazoline
Procedure · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 22, 2019 · Synced Oct 18, 2026, 5:39 AM EDT
Completed Phase 2 Interventional Results available

A Relative Efficacy and Safety Study of OC Oral Solution for Sialorrhoea in Patients With Parkinson's Disease

NCT01370811
View directory record Official record
Conditions
Sialorrhoea
Interventions
oxybutynin and clonidine oral solution treatment A, oxybutynin and clonidine oral solution treatment B, oxybutynin and clonidine oral solution treatment C, oxybutynin and clonidine oral solution treatment D
Drug
Lead sponsor
Orient Pharma Co., Ltd.
Industry
Eligibility
40 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Bingham Farms, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 10, 2023 · Synced Oct 18, 2026, 5:39 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Acute and Chronic Repercussion of Spinal Cord Stimulation After Spinal Cord Injury

NCT07210411
View directory record Official record
Conditions
Spinal Cord Injuries
Interventions
Tests of sympathetic inhibition, Tests of above level sympathetic activation, Testing of below level sympathetic activation, Epidural stimulation, Transcutaneous stimulation
Diagnostic Test · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 50 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2031
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 18, 2026, 5:39 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Pilot Study On The Role Of Nitric Oxide In Alpha 1-Adrenergic Vasoreactivity

NCT00240058
View directory record Official record
Conditions
Blood Pressure
Interventions
Regional phenylephrine arterial infusion, Nitric Oxide Clamp
Drug
Lead sponsor
Crystal A. Gadegbeku
Other
Eligibility
18 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 5, 2017 · Synced Oct 18, 2026, 5:39 AM EDT
Completed Phase 3 Interventional Results available

Safety, Efficacy and Pharmacokinetics of OMS302 in Subjects Undergoing Intraocular Lens Replacement With Phacoemulsification

NCT01579565
View directory record Official record
Conditions
Intraocular Lens Replacement
Interventions
OMS302, Placebo
Drug
Lead sponsor
Omeros Corporation
Industry
Eligibility
18 Years and older
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
13
States / cities
Chandler, Arizona • Los Angeles, California • Fort Myers, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 18, 2026, 5:39 AM EDT
Recruiting Phase 2 Interventional

Nasal Obstruction With Oxymetazoline and Corticosteroids

NCT06830109
View directory record Official record
Conditions
Nasal Obstruction
Interventions
Oxymetazoline Nasal Spray, Budesonide nasal spray
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Oct 18, 2026, 5:39 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Phenylephrine vs. Norepinephrine Infusion After Spinal Anesthesia for Cesarean Delivery

NCT02354833
View directory record Official record
Conditions
Effects of; Anesthesia, in Labor and Delivery
Interventions
Phenylephrine, Norepinephrine
Drug
Lead sponsor
West Virginia University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Jan 4, 2017 · Synced Oct 18, 2026, 5:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Electrocardiogram Results in Healthy Volunteers Receiving Canagliflozin (JNJ-28431754)

NCT01787357
View directory record Official record
Conditions
Healthy
Interventions
Canagliflozin (JNJ-28431754), Placebo, Moxifloxacin
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 29, 2016 · Synced Oct 18, 2026, 5:39 AM EDT
Completed Phase 3 Interventional

Study to Find Out Whether Participants With a History of Stuffy Nose Due to Allergic Reactions in the Nose Would Intend to Buy Drug Phenylephrine Hydrochloride Extended Release Tablets After Receiving it Once in This Study

NCT04534452
View directory record Official record
Conditions
Nasal Congestion Due to Allergic Rhinitis
Interventions
Phenylephrine HCl (Sinus Comfort, BAY112476)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 60 Years
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Blue Bell, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 1, 2020 · Synced Oct 18, 2026, 5:39 AM EDT
Recruiting Not applicable Interventional

Aspiration in Acute Respiratory Failure Survivors 2

NCT05108896
View directory record Official record
Conditions
Dysphagia, Aspiration
Interventions
3-Screenings Protocol, FEES, Tracheal Ultrasound
Diagnostic Test
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
855 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
5
States / cities
Stanford, California • Aurora, Colorado • New Haven, Connecticut + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Oct 18, 2026, 5:39 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Alpha-Adrenoceptor Vascular Function In Chronic Kidney Disease Focus On The Role Of Endothelial Nitric Oxide

NCT00356265
View directory record Official record
Conditions
Chronic Kidney Disease, Hypertension
Interventions
Procedure: Regional phenylephrine arterial infusion
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 18, 2026, 5:39 AM EDT